Siemens Healthineers Ag · XETR:SHL
Siemens Healthineers — Q3 FY2022 Earnings Presentation
20 slides from Siemens Healthineers's earnings presentation, Aug 3, 2022
Slide 1: Q3 Analyst Call
Q3 Analyst Call Bernd Montag, CEO | Jochen Schmitz, CFO Aug 03, 2022
Slide 2: Safe harbour statement
Safe harbour statement This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, you agree to be
Slide 3: Demonstrating strength in a challenging environment – Outlook confirmed
Demonstrating strength in a challenging environment – Outlook confirmed • Very strong equipment order growth continues, equipment book-to-bill at 1.31 • Y-o-y declining antigen revenue and a challenging environment in Q3, notably China lockdowns, lead to declining revenue (-5.7%; ex-antigen +0.9%) v
Slide 4: Our unique capabilities
Our unique capabilities Patient Twinning Precision Therapy Personalization of diagnosis, Intelligent and image guided therapy selection and monitoring, treatment for the most after care and managing health threatening diseases Digital, Data and AI Leveraging digital, data and AI and advance provider
Slide 5: Continued momentum in 'Value Partnerships' – Ohio State University
Continued momentum in ‘Value Partnerships’ – Exemplary partnership with The Ohio State University • Five-year strategic partnership with The Ohio State University aiming at advancing personalized medicine and improving access to high quality, cost-effective healthcare • Siemens Healthineers (Imaging
Slide 6: A unique investment case
A unique investment case – Structural and innovation driven growth paired with attractive earnings growth and resilience Structural and innovation driven growth • Essential technologies and leading innovations for fighting the most threatening diseases Unique Enabling and advancing Attractive • Cont
Slide 7: Backlog provides good topline visibility, pricing measures phase into revenue and margins
Backlog provides good topline visibility, pricing measures phase into revenue and margins over time Sizeable backlog reflects pricing measures over time Pricing will compensate for higher cost increases • Steadily increasing backlog, equipment revenues for FY23 and • Market adaptive pricing mechanis
Slide 8: Resilient growth ex-antigen, earnings held back by lower antigen contribution and China lockdowns
Resilient growth ex-antigen, earnings held back by lower antigen contribution and China lockdowns Revenue (€m) Adjusted basic earnings per share (€) Comparable PYQ: -5.7% Y-o-Y PYQ: -24% Growth +39% +84% 5,000 5,186 0.56 0.43 Q3 FY2021 Q3 FY2022 Q3 FY2021 Q3 FY2022 • Revenue in Q3 declining (-5.7%)
Slide 9: Solid revenue growth in Imaging, declining revenue in Diagnostics
Solid revenue growth in Imaging, declining revenue in Diagnostics primarily due to antigen Imaging (€m) Diagnostics (€m) Adjusted revenue Adj. EBIT (margin) Adjusted revenue Adj. EBIT (margin) Comparable Margin Comparable Margin Growth +2.5% Y-o-Y +30 bps Growth -23.9% Y-o-Y -830 bps 430 478 360 2,3
Slide 10: Strong growth in Varian and Advanced Therapies
Strong growth in Varian and Advanced Therapies Varian (€m) Advanced Therapies (€m) Adjusted revenue Adj. EBIT (margin) Adjusted revenue Adj. EBIT (margin) Comparable Margin Comparable Margin Growth +8.2% Y-o-Y -330 bps Growth +5.8% Y-o-Y -160 bps 98 107 37 35 800 397 449 591 (16.6%) (13.3%) (9.3%) (
Slide 11: Strong Q4 expected with high absolute revenue contribution
Strong Q4 expected with high absolute revenue contribution and sequential improvements vs. Q3 Revenues (in €bn) and comparable revenue growth rates Revenue drivers in Q4 +10% +16% -6% • By far strongest absolute revenue quarter due to seasonality • Varian contributing with continuing growth momentum
Slide 12: Outlook FY2022 confirmed
Outlook FY2022 confirmed Comparable revenue growth1, 2 Adj. basic earnings per share2 €2.25 to €2.35 €2.08 to €2.20 5.5 to 7.5% 0 to 2% As of Nov 2021 As of May 2022 As of Nov 2021 As of May 2022 • Imaging growth at 5 to 7% (before: 6 to 8%3) • Imaging margin at 20 to 21% (before: 21 to 22%3) • Diag
Slide 13: Appendix
Appendix Q3 FY2022 Unrestricted © Siemens Healthineers AG, 2022 l 13
Slide 14: Accretion from rapid antigen declining as expected
Accretion from rapid antigen declining as expected DX incl. rapid antigen tests DX ex rapid antigen tests Comparable revenue growth in FY22 • New rapid antigen assumption for FY22 of ~€1,500m [before: €1,300m] due to demand in Japan • ~€1,300m rapid antigen revenue year-to-date with demand further d
Slide 15: Q3 FY22 with strong cash conversion
Q3 FY22 with strong cash conversion Q3 FY22 Siemens Healthineers EBIT to Free Cash Flow (€m) Imaging 1.0 CCR1 Diagnostics 1.2 Varian 0.7 Adv. Therapies 1.0 CCR1 0.98 938′ 955′ 44′ -26′ -71′ 70′ 742′ 195′ 45′ 724′ -186′ 595′ 148′ -45′ 478′ -291′ Healthineers PPA EBIT excl. Depr. of PPE EBITDA Change
Slide 16: FY22 balance sheet and net debt bridge
FY22 balance sheet and net debt bridge Net debt overview Capital structure development in FY22 (in €bn) in €bn Sep 30, 2021 Jun 30, 2022 Leverage1 3.5x 3.2x Cash and cash equivalents 1.3 1.4 12.8 12.7 Current receivables and 0.9 0.6 receivables from the Siemens 0.6 0.5 Pensions 1.4 Group from financ
Slide 17: Loan maturity profile
Loan maturity profile Loans with Siemens Group as of Jun 30th, 20221 (in €m) Comments Other ▪ Total loan volume ~€13bn equivalent EUR ▪ Average interest rate ~0.5%3 p.a. USD 2,179 93 Top 10 loans ranked in € volume Notional Volume Volume Interest 1,730 Maturity Currency in m in €m rate 20 1,559 1,51
Slide 18: Provisions for pensions decreased mainly due to increased discount rates
Provisions for pensions decreased mainly due to increased discount rates Q3 FY2022 Key financials – Pensions and similar obligations Q1 Q2 Q3 in €bn1 FY2018 FY2019 FY2020 FY2021 FY2022 FY2022 FY2022 Defined benefit (3.4) (3.8) (3.8) (4.1) (4.1) (3.8) (3.4) obligation (DBO) Fair value of plan 2.6 2.8
Slide 19: Glossary
Glossary Adjusted revenue is defined as consolidated revenue reported in the company’s consolidated statements of income adjusted for effects in line with revaluation of contract liabilities from IFRS 3 purchase price allocations. Comparable revenue growth is defined as the development of adjusted r
Slide 20: Q3 FY2022 Unrestricted © Siemens Healthineers AG, 2022 l 20
Q3 FY2022 Unrestricted © Siemens Healthineers AG, 2022 l 20
Siemens Healthineers — Q3 FY2022 Earnings Presentation on 6ix